Clinical trials: Type 2 Diabetes Patients
Diabetes Mellitus, Type 2
A Prospective Study to Evaluate Revita DMR Post Market Pilot Clinical Follow-Up Registry in Patient With Type 2 Diabetes
The Revita DMR Post Market Pilot Clinical Registry is a post-market, prospective, observational, noninterventional clinical registry in patients with T2D in Germany undergoing the Revita Procedure with the CE marked Revita System…
- Trial name
- NCT06256497
- Testing
- Duodenal Mucosal Resurfacing (DMR)
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Fractyl Health Inc.
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without metformin over a period of 24 weeks of treatment…
- Trial name
- GETGOAL-L (NCT00715624)
- Testing
- Lixisenatide (AVE0010), Basal Insulin, Metformin
- Where
- 15 sites in United States, Brazil and 13 more
- Volunteers
- 496 people
- Sponsor
- Sanofi
Glycemia, Hypertension
Effect of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).
This study will address the proportion of achievement patients in treatment target goal on glycemic control, hypertension and hyperlipidemia according to ADA 2008 guideline, among outpatients coming to the Korean primary care…
- Conditions
- Glycemia, Hypertension, Hyperlipidemia
- Trial name
- PATROL (NCT00891124)
- Where
- 7 sites in South Korea
- Volunteers
- 4,045 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes
A study to evaluate the efficacy and safety of Human Insulin Inhalation Powder [also known as AIR® Inhaled Insulin][AIR® is a registered trademark of Alkermes,Inc.] in patients with Type 2 diabetes who are currently being treated…
- Trial name
- NCT00355849
- Testing
- Human Insulin Inhalation Powder, Insulin Glargine
- Where
- 69 sites in United States, Brazil and 10 more
- Volunteers
- 555 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes
The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to sulfonylurea alone or in combination with other anti-diabetic drugs.
- Trial name
- NCT00147758
- Testing
- Colesevelam hydrochloride
- Where
- 47 sites in United States, Mexico and 1 more
- Volunteers
- 400 people
- Sponsor
- Daiichi Sankyo
Type II Diabetes Mellitus
A Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With Type 2 Diabetes Mellitus
A real-world, point-of-care, randomized, parallel group, open, 6-month clinical study to evaluate if the provision of a digital disease management tool improves glycaemic control in participants with type 2 diabetes mellitus…
- Trial name
- NCT02749435
- Testing
- Use of digital disease management tool in participants with T2DM
- Where
- 14 sites in United Kingdom
- Volunteers
- 57 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus (T2DM)
Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.
This study was aimed to achieve of long-term weight loss in T2DM patients by use of comprehensive lifestyle changes program, providing patients with structured diet, exercise plan, group behavioral support and group education.
- Trial name
- NCT02670928
- Testing
- Lifestyle intervention
- Where
- 2 sites in Russia
- Volunteers
- 130 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
User Experience With DuraTouch® in Patients With Type 1 or Type 2 Diabetes
This study looks at overall impact of the use of DuraTouch® in terms of ease, convenience to use and satisfaction in participants with either type 1 or type 2 diabetes.The study will last for about 12 weeks.
- Trial name
- NCT07052292
- Testing
- DuraTouch®
- Where
- 11 sites in Poland
- Volunteers
- 128 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin
Primary Objective: To assess the effects on glycemic control of lixisenatide in comparison to placebo as an add-on treatment to basal insulin with or without metformin in terms of HbA1c reduction over a period of 24 weeks in…
- Trial name
- NCT01632163
- Testing
- Lixisenatide (AVE0010)
- Where
- 51 sites in China, India and 2 more
- Volunteers
- 447 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065)
This is a study to evaluate the effectiveness and tolerability of an investigational drug in patients with type 2 diabetes (a specific type of diabetes) who are not currently treated with insulin.
- Trial name
- NCT00130806
- Testing
- MK0478 (muraglitazar)
- Volunteers
- 600 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus, Hypertension
Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)
The study will assess the efficacy and tolerability of MK0736 in patients with Type 2 Diabetes Mellitus and Hypertension who are on ongoing therapy with Angiotensin-Converting Enzyme or Angiotensin Receptor Blocker.
- Trial name
- NCT00806585
- Testing
- MK-0736, Comparator: HCTZ
- Volunteers
- 620 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes
Many people with type 2 diabetes cannot maintain their target blood glucose levels on a single therapy. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, in lowering overall…
- Trial name
- NCT00099931
- Testing
- vildagliptin
- Where
- Germany
- Volunteers
- 254 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes
Effects of Genmont Probiotic on Improve the Level of Blood Glucose and Other Diabetic Associate Parameter in Type 2 Diabetes Patients
The purpose of this study is to evaluate the efficacy and safety of probiotics ADR-1/GMNL-263 capsules (Lactobacillus reuteri ADR-1/ Lactobacillus reuteri GMNL-263) for the treatment of adults with type2 DM.
- Trial name
- NCT02274272
- Testing
- ADR-1, GMNL-263
- Where
- Taiwan
- Volunteers
- 86 people
- Sponsor
- GenMont Biotech Incorporation
Glucose Lowering
To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients
To assess the pharmacokinetics of AZD1656, and its metabolite, in type 2 diabetes mellitus patients with varying degrees of renal impairment and to compare the results with those in patients with normal renal function.
- Trial name
- NCT01069926
- Testing
- AZD1656
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Multiple-Ascending Dose Study in Type 2 Diabetes Mellitus Patients
The study drug LY2393910 is being evaluated as a possible treatment for diabetes. The primary purpose of a patient's participation in this study is to help answer the following research question(s), and not to provide treatment…
- Trial name
- NCT01253278
- Testing
- LY2393910
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus, CKD and Albuminuria
A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD
The purpose of this clinical research study is to determine whether dapagliflozin alone or in combination with saxagliptin can decrease albuminuria and improve glycemic control in patients with Type 2 diabetes, albuminuria and…
- Trial name
- NCT02547935
- Testing
- Dapagliflozin 10 mg, Saxagliptin 2.5 mg
- Where
- 112 sites in United States, Australia and 7 more
- Volunteers
- 459 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients
This study will assess the efficacy of vildagliptin plus metformin (SPC) treatment in type 2 diabetes mellitus patients uncontrolled by metformin monotherapy after 24 weeks treatment
- Trial name
- NCT01582243
- Testing
- Vildagliptin
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
The objective is to investigate the efficacy, safety and pharmacokinetics of three different doses of BI 10773 compared to placebo given for 12 weeks in patients with type 2 diabetes mellitus with insufficient glycemic control.
- Trial name
- NCT00789035
- Testing
- BI 10773, metformin
- Where
- 74 sites in Argentina, Croatia and 11 more
- Volunteers
- 408 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus
This randomized, multicenter, open-label, active-comparator, 2-arm, parallel-group, 6 month study with approximately 360 patients will compare the efficacy of two treatment regimens (Algorithm A versus Algorithm B) in…
- Trial name
- NCT00391209
- Testing
- simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder, intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder
- Where
- 42 sites in United States, Argentina and 7 more
- Volunteers
- 379 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type 2
Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy
Primary objective of this study is to compare diabetes-related healthcare utilization and costs in patients initiating exenatide once weekly vs insulin glargine.
- Trial name
- NCT02843399
- Where
- United States
- Volunteers
- 15,498 people
- Sponsor
- AstraZeneca